thalidomide (Thalamid, Corronarobetin)
Jump to navigation
Jump to search
Introduction
Special prescribing requirements. Prescribers & pharmacists must be registered with the System for Thalidomide Education & Prescribing Safety (S.T.E.P.S.) to prescribe or dispense Thalomid.[3]
Indications
- erythema nodosum of leprosy
- lichen planus
- multiple myeloma (combination chemotherapy)
- subacute cutaneous lupus erythematosus[5]
- discoid lupus erythematosus
- actinic prurigo
- aphthous stomatitis
- graft vs host disease[5]
- refractory Crohn's disease[6]
- recurrent small-intestinal angiodysplasia[8]
Contraindications
- pregnancy
- use in patients with renal insufficiency has not been established[4]
Dosage
Adverse effects
- teratogenic, do not use in woman of child-bearing age
- phocomelia, cardiac anomalies
- peripheral neuropathy
- dizziness & orthostatic hypotension
- neutropenia
- may increase viral load in HIV+ patients
- bradycardia
- venous thromboembolism*
- neutrophilic dermatosis
- constipation, somnolence, limb numbness, peripheral edema, elevated serum transaminases[8]
* prophylaxis for deep vein thrombosis
Mechanism of action
- immune modulation
- angiogenesis inhibitor
- alterations in expression of
More general terms
Additional terms
Component of
- recombinant parathyroid hormone (1-84) (Natpara)
- dexamethasone/thalidomide (ThaD)
- thalidomide, dexamethasone & pegylated liposomal doxorubicin (ThADD)
- melphalan/prednisone/thalidomide (ThaMP)
References
- ↑ Harrison's Principles of Internal Medicine, 13th ed. Isselbacher et al (eds), McGraw-Hill Inc. NY, 1994, pg 1039
- ↑ Thalidomide Continues Its Comeback Against Multiple Myeloma http://www.nci.nih.gov/clinicaltrials/results/thalidomide-comeback0500
- ↑ 3.0 3.1 System for Thalidomide Education & Prescribing Safety (S.T.E.P.S.) to prescribe or dispense Thalomid. (888) 423-5436
- ↑ 4.0 4.1 Geriatric Review Syllabus, 7th edition Parada JT et al (eds) American Geriatrics Society, 2010
- ↑ 5.0 5.1 5.2 Deprecated Reference
- ↑ 6.0 6.1 Lazzerini M et al Effect of Thalidomide on Clinical Remission in Children and Adolescents With Refractory Crohn Disease. A Randomized Clinical Trial. JAMA. 2013;310(20):2164-2173 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24281461 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1785463
- ↑ 7.0 7.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ 8.0 8.1 8.2 Chen H, Wu S, Tang M et al. Thalidomide for recurrent bleeding due to small-intestinal angiodysplasia. N Engl J Med 2023 Nov 2; 389:1649. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37913505 Clinical Trial. https://www.nejm.org/doi/10.1056/NEJMoa2303706